Lancet Oncol 2017 Jun
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Related Questions
What treatment options would you consider for a metastatic low grade serous ovarian carcinoma that transforms to high grade?
1 Answers
Mednet Member
Gynecologic Oncology · UCLA David Geffen School of Medicine/UCLA Medical Center
A couple of things to consider for this case, #1 treatment-free interval #2 platinum-free interval #3 bulky disease? #4 recent tumor profiling #5 HRD status? I am assuming that she is motivated to continue treatment. If she had a good and durable response to platinum-doublet in the past then I might...
Do you recommend bevacizumab in platinum sensitive recurrences of epithelial ovarian cancer?
1 Answers
Mednet Member
Gynecologic Oncology · Vanderbilt University School of Medicine
Bevacizumab was approved for use in combination with chemotherapy followed by continued bevacizumab maintenance in patients with platinum-sensitive recurrent ovarian cancer in December 2016. This approval was based on the findings of 2 studies, GOG-213 and the OCEANS trial. Both trials demonstrated ...